Innogen Pharmaceuticals Enters into Licensing Agreement with Arcera Life Sciences for Efsubaglutide Alfa, Accelerating International Expansion

The Quick Take
Under the agreement, Arcera will obtain exclusive rights to Efsubaglutide Alfa in selected countries in Africa, Latin America, the Middle East and Eastern Europe, while Innogen retains the relevant rights in the rest of the world. Under the agreement, Innogen will receive US$38 million in...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Business
NetEase ADR earnings missed by ¥2.23, revenue fell short of estimates
Business
Nanoform Q3 2026 slides: expenses down 35%, GMP readiness nears
Business
Futu earnings missed by HK$1.07, revenue topped estimates
Business
